TY - JOUR
T1 - The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer
T2 - results from a pooled-analysis of the Valentino and TRIBE first-line trials
AU - Fucà, Giovanni
AU - Guarini, Vincenzo
AU - Antoniotti, Carlotta
AU - Morano, Federica
AU - Moretto, Roberto
AU - Corallo, Salvatore
AU - Marmorino, Federica
AU - Lonardi, Sara
AU - Rimassa, Lorenza
AU - Sartore-Bianchi, Andrea
AU - Borelli, Beatrice
AU - Tampellini, Marco
AU - Bustreo, Sara
AU - Claravezza, Matteo
AU - Boccaccino, Alessandra
AU - Murialdo, Roberto
AU - Zaniboni, Alberto
AU - Tomasello, Gianluca
AU - Loupakis, Fotios
AU - Adamo, Vincenzo
AU - Tonini, Giuseppe
AU - Cortesi, Enrico
AU - de Braud, Filippo
AU - Cremolini, Chiara
AU - Pietrantonio, Filippo
PY - 2020/8
Y1 - 2020/8
N2 - BACKGROUND: Immune-inflammatory biomarkers (IIBs) showed a prognostic relevance in patients with metastatic CRC (mCRC). We aimed at evaluating the prognostic power of a new comprehensive biomarker, the Pan-Immune-Inflammation Value (PIV), in patients with mCRC receiving first-line therapy.METHODS: In the present pooled-analysis, we included patients enrolled in the Valentino and TRIBE trials. PIV was calculated as: (neutrophil count × platelet count × monocyte count)/lymphocyte count. A cut-off was determined using the maximally selected rank statistics method. Generalised boosted regression (GBR), the Kaplan-Meier method and Cox hazards regression models were used for survival analyses.RESULTS: A total of 438 patients were included. Overall, 208 patients (47%) had a low-baseline PIV and 230 (53%) had a high-baseline PIV. Patients with high PIV experienced a worse PFS (HR, 1.66; 95% CI, 1.36-2.03, P < 0.001) and worse OS (HR, 2.01; 95% CI, 1.57-2.57; P < 0.001) compared to patients with low PIV. PIV outperformed the other IIBs in the GBR model and in the multivariable models.CONCLUSION: PIV is a strong predictor of survival outcomes with better performance than other well-known IIBs in patients with mCRC treated with first-line therapy. PIV should be prospectively validated to better stratify mCRC patients undergoing first-line therapy.
AB - BACKGROUND: Immune-inflammatory biomarkers (IIBs) showed a prognostic relevance in patients with metastatic CRC (mCRC). We aimed at evaluating the prognostic power of a new comprehensive biomarker, the Pan-Immune-Inflammation Value (PIV), in patients with mCRC receiving first-line therapy.METHODS: In the present pooled-analysis, we included patients enrolled in the Valentino and TRIBE trials. PIV was calculated as: (neutrophil count × platelet count × monocyte count)/lymphocyte count. A cut-off was determined using the maximally selected rank statistics method. Generalised boosted regression (GBR), the Kaplan-Meier method and Cox hazards regression models were used for survival analyses.RESULTS: A total of 438 patients were included. Overall, 208 patients (47%) had a low-baseline PIV and 230 (53%) had a high-baseline PIV. Patients with high PIV experienced a worse PFS (HR, 1.66; 95% CI, 1.36-2.03, P < 0.001) and worse OS (HR, 2.01; 95% CI, 1.57-2.57; P < 0.001) compared to patients with low PIV. PIV outperformed the other IIBs in the GBR model and in the multivariable models.CONCLUSION: PIV is a strong predictor of survival outcomes with better performance than other well-known IIBs in patients with mCRC treated with first-line therapy. PIV should be prospectively validated to better stratify mCRC patients undergoing first-line therapy.
U2 - 10.1038/s41416-020-0894-7
DO - 10.1038/s41416-020-0894-7
M3 - Article
C2 - 32424148
VL - 123
SP - 403
EP - 409
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 3
ER -